1241P - Afatinib efficacy and cerebrospinal fluid concentration in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Non-Small-Cell Lung Cancer, Metastatic
Presenter Akihiro Tamiya
Citation Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383
Authors A. Tamiya1, M. Tamiya2, T. Nishihara2, T. Shiroyama2, K. Nakao1, T. Tsuji1, N. Takeuchi1, S. Isa3, N. Omachi1, N. Okamoto4, H. Suzuki4, K. Okishio3, A. Iwazaki5, K. Imai5, T. Hirashima2, S. Atagi3
  • 1Internal Medicene, Kinki-chuo Chest Medical Center, 591-8555 - Sakai/JP
  • 2Department Of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 583-8588 - Habikino/JP
  • 3Clinical Research Center, Kinki-chuo Chest Medical Center, 591-8555 - Sakai/JP
  • 4Thoracic Malignancy, Osaka Prefectural Hospital Organization Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 583-8588 - Habikino/JP
  • 5Pharmaceutical Sciences, Setsunan University, Hirakata/JP

Abstract

Background

Afatinib (AFA) is an effective treatment in advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutation. However, there are few reports about the cerebrospinal fluid (CSF) penetration rate and the efficacy for trreatment of central nervous system (CNS) metastasis. Therefore, we conducted a study to evaluate the CSF penetration rate and efficacy of AFA in NSCLC patients harboring EGFR mutation with leptomeningeal carcinomatosis (LC).

Methods

Eligibility criteria included performance status (PS) 0-3, aged 20 years or older, pathologically proven NSCLC, harboring EGFR mutation, with LC, adequate organ function, and written informed consent. Patients received AFA (40mg/body every day). We analyzed the blood and CSF level of AFA before administrating AFA on the eighth day. The primary endpoint was the CSF penetration rate. Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety profile.

Results

A total of 11 patients were enrolled. And we could analyze the blood level in 10 patients and the CSF level in 8 patients. Median patient age was 66 years. All patients were adenocarcinoma. In EGFR mutation status, 5 patients had exon 19 deletion, 3 had L858R and 3 had minor (exon18) mutation. There were 3 patients of PS2 and 4 patients were PS3. Almost all patients received AFA after third-line or further line chemotherapy. The median blood level was the 88.2 (range: 30.4-373) ng/ml, the median CSF level was 1.4 (range: 0.39-2.85) ng/ml and the median CSF penetration rate was 1.65 (range: 0.1-9.25) %. The ORR was 27.3%. Median OS was 3.8 (95%CI: 1.1-13.1) months and median PFS was 2.0 (95%CI: 0.6-5.8) months. Hematological toxicity was mild; however diarrhea and skin toxicities were relatively strong, especially in patients with poor PS.

Conclusions

The median CSF penetration rate of AFA was higher than the rate in previous reports; however the rate was lower compared with that of erlotinib in the prior reports. The efficacy for LC was moderate. And we have to take care of diarrhea and skin toxicities, especially in the patients with poor PS.

Clinical trial identification

UMIN000014065

Legal entity responsible for the study

Shinji Atagi

Funding

Kinki-Chuo Chest Medical Center

Disclosure

T. Hirashima: Astra Zeneka, Chugai Pharmaceutical Co., Inc., MSD, Merck & Co., Inc., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd. S. Atagi: Honoraria: Eli Lilly Japan, Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, Pfizer Japan, Ono Pharmaceutical, and AstraZeneca. Research funding: Chugai Pharmaceutical, Pfizer, Ono Pharmaceutical, Merck Serono, Boehringer Ingelheim. All other authors have declared no conflicts of interest.